According to this Form 4 filing, the CMO of UroGen Pharma sold 10,000 shares at $40.00 per share, totaling $400,000 in transaction proceeds. The sale represented 8% of the insider's direct equity holdings in the company, as reported in the Form 4.

fool.com - 2026-07-12 14:11:56

FDA clearance enables initiation of a planned Phase 1 clinical study evaluating local intravesical administration of UGN-501, with patient enrollment expected to begin in Q4 2026 UGN-501 is a differentiated investigational next-generation oncolytic virus designed to combine direct tumor cell destruction with anti-tumor immune activation PRINCETON, N.J., July 08, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.

globenewswire.com - 2026-07-08 08:00:00

Does Urogen Pharma (URGN) have what it takes to be a top stock pick for momentum investors? Let's find out.

zacks.com - 2026-07-07 13:01:17

10,000 shares were sold for a transaction value of ~$350,000 at a weighted average price of around $35.01 per share on June 22, 2026. The sale represented 7.15% of Mark Schoenberg's direct holdings, reducing his position from 139,763 to 129,763 shares of common stock.

fool.com - 2026-06-30 23:38:01

5,222 shares were sold on June 8, 2026 for a transaction value of approximately $143,000 at a weighted average price around $27.30 per share. The transaction represented 3.60% of Mark Schoenberg's direct holdings, reducing his position from 144,985 to 139,763 shares.

fool.com - 2026-06-14 11:14:38

UroGen Pharma Ltd. (URGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-10 14:42:17

PRINCETON, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.

globenewswire.com - 2026-06-05 08:00:00

Agreement reinforces the value of UroGen's innovation and reflects the strength of the Company's intellectual property portfolio Teva will be granted a non-exclusive license to sell its generic version of JELMYTO beginning on September 15, 2030, if approved by the FDA PRINCETON, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.

globenewswire.com - 2026-06-02 08:00:00

PRINCETON, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced that management will present at the Goldman Sachs 47th Annual Global Healthcare Conference to take place on June 8-10, 2026.

globenewswire.com - 2026-06-01 16:10:00

PRINCETON, N. J. , June 01, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced that management will present at the Goldman Sachs 47th Annual Global Healthcare Conference to take place on June 8-10, 2026.

globenewswire.com - 2026-06-01 16:10:00

UroGen Pharma Ltd. (URGN) Discusses Real-World Experiences and Outcomes With ZUSDURI for Recurrent Bladder Cancer Transcript

seekingalpha.com - 2026-05-17 14:30:41

PRINCETON, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.

globenewswire.com - 2026-05-15 08:00:00

UroGen Pharma Ltd. (URGN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-05-13 13:20:45

64.5% Probability of Remaining Event-Free at Three Years by Kaplan-Meier Analysis After Achieving Complete Response at Three Months First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer PRINCETON, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.

globenewswire.com - 2026-05-13 08:00:00

From a technical perspective, Urogen Pharma (URGN) is looking like an interesting pick, as it just reached a key level of support. URGN's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.

zacks.com - 2026-05-11 10:56:13

UroGen Pharma is reaffirmed as a Strong Buy, with a 12-month price target raised to $39/share, reflecting robust Q1 2026 results. Zusduri sales more than doubled QoQ to $29.2M, driven by the January J-code assignment, validating the trajectory toward profitability by 2027. URGN's path to profitability is underpinned by >91% gross margins, disciplined expense control, and a realistic break-even threshold of $305M annual revenue.

seekingalpha.com - 2026-05-07 15:59:46

PRINCETON, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.

globenewswire.com - 2026-05-07 08:00:00

UroGen Pharma Ltd. (URGN) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-06 18:01:17

Urogen Pharma (URGN) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to a loss of $0.92 per share a year ago.

zacks.com - 2026-05-06 10:30:27

ZUSDURI™ generated revenue of $29.2 million in Q1 2026, representing 109% quarter-over-quarter growth, reflecting broader utilization with the permanent J Code effective January 1, 2026 JELMYTO achieved $21.7 million in revenue in Q1 2026, representing year-over-year growth of 7% Continued advancement of next-generation pipeline, UGN-103 on track for NDA submission in the second half of 2026; six-month durability data expected in mid-2026 UroGen to host Key Opinion Leader (KOL) panel highlighting real-world experience with ZUSDURI at the American Urological Association (AUA) annual meeting on May 17 th at 8:30 AM ET Conference call and webcast to be held today at 10:00 AM ET PRINCETON, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.

globenewswire.com - 2026-05-06 08:00:00

Conference Call and Webcast Scheduled for Wednesday, May 6th, 2026, at 10:00 AM ET Conference Call and Webcast Scheduled for Wednesday, May 6th, 2026, at 10:00 AM ET

globenewswire.com - 2026-04-29 08:00:00